Lexicon Pharmaceuticals (LXRX) Other Non-Current Assets (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Other Non-Current Assets of $368000.0 for Q1 2026, little changed year-over-year from $368000.0 in Q1 2025, and down 98.73% quarter-over-quarter from $29.0 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Other Non-Current Assets data on file, last reported at $368000.0 in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $368000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $368000.0 (changed 0.0% YoY), and the FY2025 annual result was $29.0 million, changed N/A from the prior year.
- Other Non-Current Assets slipped to $368000.0 in Q1 2026 per LXRX's latest filing, from $29.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $29.0 million in Q3 2025 and troughed at $368000.0 in Q1 2025.
- A 5-year average of $5.5 million and a median of $828000.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets sank 89.6% in 2023, then jumped 3402.42% in 2025.
- A 5-year view of Other Non-Current Assets shows it stood at $412000.0 in 2022, then jumped by 100.97% to $828000.0 in 2023, then changed by 0.0% to $828000.0 in 2024, then jumped by 3402.42% to $29.0 million in 2025, then tumbled by 98.73% to $368000.0 in 2026.
- Business Quant data shows LXRX's Other Non-Current Assets at $368000.0 in Q1 2026, $29.0 million in Q4 2025, and $29.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | 368,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 368,000.00 |
| Dec 31, 2025 | 29.00 Mn |
| Sep 30, 2025 | 29.00 Mn |
| Jun 30, 2025 | 368,000.00 |
| Mar 31, 2025 | 368,000.00 |
| Sep 30, 2024 | 828,000.00 |
| Jun 30, 2024 | 828,000.00 |
| Mar 31, 2024 | 828,000.00 |
| Dec 31, 2023 | 828,000.00 |
| Sep 30, 2023 | 743,000.00 |
| Jun 30, 2023 | 6.26 Mn |
| Mar 31, 2023 | 6.42 Mn |
| Dec 31, 2022 | 412,000.00 |
| Sep 30, 2022 | 7.15 Mn |
| Jun 30, 2022 | 1.85 Mn |
| Mar 31, 2022 | 2.06 Mn |
| Dec 31, 2021 | 2.27 Mn |
| Sep 30, 2021 | 2.47 Mn |
| Jun 30, 2021 | 2.67 Mn |
| Mar 31, 2021 | 3.01 Mn |